🩸 Erythropoietin is not just a protein, but a complex glycoprotein hormone that is key to red blood cell production. Its history is impressive: from the first observations of hypoxia in the 19th century to gene cloning and the creation of recombinant drugs.
🧬 Structure and Function The erythropoietin molecule is richly “decorated” with carbohydrate chains (glycosylated). This is not just decoration: glycosylation determines the hormone’s stability, its binding to receptors, and ultimately, its therapeutic potential.
👶 Developmental Path Interesting fact: the site of erythropoietin synthesis changes with age. In the fetus, it is produced in the liver, and after birth, special kidney cells (interstitial fibroblasts) take over the main function.
⚙ Regulation Mechanisms How does the body know it needs more red blood cells? The main signal is hypoxia (lack of oxygen). 📉 During hypoxia, a key protein is activated — hypoxia-inducible factor 2-alpha (HIF-2α). Like a molecular switch, it activates the erythropoietin gene.
🧐 New Discoveries Recent genetic studies have identified variants in the erythropoietin gene that can lead to erythrocytosis (an excess of red blood cells). Surprisingly, in such patients, erythropoietin resembles the “hepatic” form characteristic of newborns in its properties. This suggests that reactivation of erythropoietin synthesis in the liver may be therapeutically beneficial, as the “hepatic” variant has increased activity.
💊 Clinical Application Erythropoiesis-stimulating agents have revolutionized the treatment of anemia. However, a new class of drugs — HIF prolyl hydroxylase inhibitors — represents a more physiological approach. They do not replace the hormone but stabilize HIF, allowing the body to synthesize erythropoietin itself and simultaneously coordinate iron metabolism.
🔭 Prospects and Challenges Despite progress, unresolved issues remain: for example, the lack of precise cellular models for studying human erythropoietin synthesis in the laboratory. A comprehensive approach, combining genetics, epigenomics, and developmental biology, opens new horizons for the therapy of erythropoiesis disorders.
The study of erythropoietin continues, promising new discoveries in oxygen homeostasis management.
Source: Salam Idriss, David Hoogewijs, François Girodon, Betty Gardie (2026). Erythropoietin Expression and Regulation: Piecing Together Known Mechanisms and Emerging Insights.
